View More View Less
  • 1 Debreceni Egyetem, Általános Orvostudományi Kar, Debrecen
Restricted access

Absztrakt

Bevezetés: A Hodgkin-lymphoma 80–90%-ban gyógyítható, azonban a betegek körülbelül 30%-a relabál, és csak ezeknek a betegeknek a felében érhető el gyógyulás autológ őssejt-transzplantáció alkalmazásával. Célkitűzés: 1980. január 1. és 2014. december 31. között kezelt és gondozott Hodgkin-lymphomás betegek túlélési adatainak, a relapsusok gyakoriságának elemzése, az új terápiás lehetőségek bemutatása. Módszer: A betegek adatainak retrospektív elemzése. Eredmények: Összesen 715 beteget kezeltek (382 férfi és 333 nő, átlagéletkoruk a betegség diagnosztizálásakor 38 év). A relabáló betegek aránya a legutolsó időszakban 24,87%-ról 8,04%-ra csökkent. Az elvégzett autológ haemopoeticus transzplantációk száma a relabáló/refrakter betegek között nőtt, 2000-től kezdve 75%-ot ért el. A teljes túlélés szignifikánsan javult; az 5 éves teljes túlélés 1980–1989 között 64,4%, 1990–1999 között 82,4%, 2000–2009 között 88,4%, 2010–2014 között 87,1% volt. A relapsusmentes túlélés nem mutatott szignifikáns változást. Következtetések: A kezelési eredmények javultak. A relabáló és refrakter betegeknek az utóbbi évek új kezelési lehetőségei nyújthatnak még több esélyt a gyógyulásra. Orv. Hetil., 2015, 156(45), 1824–1833.

  • 1

    Bonadonna, G., Bonfante, V., Viviani, S., et al.: ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J. Clin. Oncol., 2004, 22(14), 2835–2841.

  • 2

    Engert, A., Diehl, V., Franklin, J., et al.: Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J. Clin. Oncol., 2009, 27(27), 4548–4554.

  • 3

    Majhail, N. S., Weisdorf, D. J., Defor, T. E., et al.: Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s lymphoma. Biol. Blood Marrow Transplant., 2006, 12(10), 1065–1072.

  • 4

    Crump, M.: Management of Hodgkin lymphoma in relapse after autologous stem cell transplant. Hematology Am. Soc. Hematol. Educ. Program, 2008, 2008(1), 326–333.

  • 5

    Kewalramani, T., Nimer, S. D., Zelenetz, A. D., et al.: Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin’s disease or aggressive non-Hodgkin’s lymphoma. Bone Marrow Transplant., 2003, 32(7), 673–679.

  • 6

    Lukes, R. J., Craver, L. F., Hall, T. C.: Report of the nomenclature committee. Cancer Res., 1966, 26, 1311.

  • 7

    Harris, N. L., Jaffe, E. S., Diebold, J., et al.: The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology, 2000, 36(1), 69–86.

  • 8

    Carbone, P. P., Kaplan, H. S., Musshoff, K.: Report of the committee on Hodgkin’s disease staging classification. Cancer Res., 1971, 31(11), 1860–1861.

  • 9

    Lister, T. A., Crowther, D., Sutcliffe, S. B., et al.: Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J. Clin. Oncol., 1989, 7(11), 1630–1636.

  • 10

    Miltenyi, Z., Barna, S., Garai, I., et al.: Prognostic value of interim and restaging PET/CT in Hodgkin lymphoma. Results of the CHEAP (Chemotherapy Effectiveness Assessment by PET/CT) study – long term observation. Neoplasma, 2015, 62(4), 627–634.

  • 11

    Castagna, L., Carlo-Stella, C., Mazza, R., et al.: Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Mediterr. J. Hematol. Infect. Dis., 2015, 7(1), e2015015.

  • 12

    Masszi, T.: Hemopoietic stem cell transplantation in Hungary: activity and indications. [Hemopoietikus őssejt-transzplantáció Magyarországon: aktivitás és indikációk.] Transzfúzió, 2000, 33(2), 67–71. [Hungarian]

  • 13

    Pinto, A., Corradini, P., Mussetti, A., et al.: Recurrent Hodgkin lymphoma: toward a new definition of candidates for autologous stem cell transplant in the era of positron emission tomography scan and novel agents. Leuk. Lymphoma, 2015, 56(7), 1969–1974.

  • 14

    Martínez, C., Canals, C., Sarina, B., et al.: Identification of prognostic factors predicting outcome in Hodgkin’s lymphoma patients relapsing after autologous stem cell transplantation. Ann. Oncol., 2013, 24(9), 2430–2434.

  • 15

    Moskowitz, A. J., Perales, M. A., Kewalramani, T., et al.: Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br. J. Haematol., 2009, 146(2), 158–163.

  • 16

    Samaras, P., Zardavas, D., Petrausch, U., et al.: Prognostic factors for survival in lymphoma patients after autologous stem cell transplantation. Swiss Med. Wkly, 2013, 143, w13791.

  • 17

    Nieto, Y., Popat, U., Anderlini, P., et al.: Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin’s lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. Biol. Blood Marrow Transplant., 2013, 19(3), 410–417.

  • 18

    Visani, G., Malerba, L., Stefani, P. M., et al.: BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood, 2011, 118(12), 3419–3425.

  • 19

    Musso, M., Scalone, R., Marcacci, G., et al.: Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study. Bone Marrow Transplant., 2010, 45(7), 1147–1153.

  • 20

    Di Ianni, M., Ballanti, S., Iodice, G., et al.: High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk Hodgkin’s lymphoma. Hematology, 2012, 17(1), 23–27.

  • 21

    Arai, S., Fanale, M., DeVos, S., et al.: Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk. Lymphoma, 2013, 54(11), 2531–2533.

  • 22

    Sarina, B., Castagna, L., Farina, L., et al.: Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood, 2010, 115(18), 3671–3677.

  • 23

    Sureda, A., Robinson, S., Canals, C., et al.: Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J. Clin. Oncol., 2008, 26(3), 455–462.

  • 24

    Corradini, P., Sarina, B., Farina, L.: Allogeneic transplantation for Hodgkin’s lymphoma. Br. J. Haematol., 2011, 152(3), 261–272.

  • 25

    Robinson, S. P., Sureda, A., Canals, C., et al.: Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin’s lymphoma: identification of prognostic factors predicting outcome. Haematologica, 2009, 94(2), 230–238.

  • 26

    Currin, E. S., Gopal, A. K.: Treatment strategies for Hodgkin lymphoma recurring following autologous hematopoietic stem cell transplantation. Korean J. Hematol., 2012, 47(1), 8–16.

  • 27

    Luznik, L., O’Donnell, P. V., Symons, H. J., et al.: HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol. Blood Marrow Transplant., 2008, 14(6), 641–650.

  • 28

    Burroughs, L. M., O’Donnell, P. V., Sandmaier, B. M., et al.: Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol. Blood Marrow Transplant., 2008, 14(11), 1279–1287.

  • 29

    Raiola, A., Dominietto, A., Varaldo, R., et al.: Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin’s lymphoma. Bone Marrow Transplant., 2014, 49(2), 190–194.

  • 30

    Gayoso, J., Balsalobre, P., Castilla-Llorente, C., et al.: Haploidentical stem cell transplantation (HAPLO-HSCT) with reduced intensity conditioning (RIC) regimens and high dose cyclophosphamide post-transplant (HD-CY) as GVHD prophylaxis in patients with relapsed or refractory Hodgkin´s disease: multicentric Spanish experience. Blood, 2013, 122(21), 3406.

  • 31

    Illés, Á., Jóna, Á., Miltényi, Zs.: Brentuximab vedotin for treating Hodgkin’s lymphoma: an analysis of pharmacology and clinical efficacy. Expert Opin. Drug Metab. Toxicol., 2015, 11(3), 451–459.

  • 32

    Moskowitz, C. H., Nadamanee, A., Masszi, T., et al.: Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 2015, 385(9980), 1853–1862.

  • 33

    Cheson, B. D., Rummel, M. J.: Bendamustine: Rebirth of an old drug. J. Clin. Oncol., 2009, 27(9), 1492–1501.

  • 34

    Provencio, M., Sánchez, A., Sánchez-Beato, M.: New drugs and targeted treatments in Hodgkin’s lymphoma. Cancer Treat. Rev., 2014, 40(3), 457–464.

  • 35

    Derenzini, E., Zinzani, P. L., Cheson, B. D.: Bendamustine: role and evidence in lymphoma therapy, an overview. Leuk. Lymphoma, 2014, 55(7), 1471–1478.

  • 36

    Moskowitz, A. J., Hamlin, P. A. Jr., Perales, M. A., et al.: Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J. Clin. Oncol., 2013, 31(4), 456–460.

  • 37

    Corazzelli, G., Angrilli, F., D’Arco, A., et al.: Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma. Br. J. Haematol., 2013, 160(2), 207–215.

  • 38

    LaCasce, A., Bociek, G. R., Matous, J., et al.: Brentuximab vedotin in combination with bendamustine for patients with Hodgkin lymphoma who are relapsed or refractory after frontline therapy. (ASH Ann. Meet. Abstr.) Blood, 2014, 124(21), 293.

  • 39

    Tageja, N., Nagi, J.: Bendamustine: something old, something new. Cancer Chemother. Pharmacol., 2010, 66, 413–423.

  • 40

    Ansell, S. M., Lesokhin, A. M., Borrello, I., et al.: PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N. Engl. J. Med., 2015, 372(4), 311–319.

  • 41

    Moskowitz, C. H., Ribrag, V., Michot, J. M., et al.: PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a phase 1b study (KEYNOTE-013). (ASH Ann. Meet. Abstr.) Blood, 2014, 124(21), 290.

  • 42

    Younes, A., Sureda, A., Ben-Yehuda, D., et al.: Panobinostat in patients with relapsed/refractory Hodgkin’s lymphoma after autologous stem-cell transplantation: results of a phase II study. J. Clin. Oncol., 2012, 30(18), 2197–2203.

  • 43

    Younes, A., Oki, Y., Bociek, R. G., et al.: Mocetinostat for relapsed classical Hodgkin’s lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol., 2011, 12(13), 1222–1228.

  • 44

    Younes, A., Hernandez, F., Bociek, R. G., et al.: ENGAGE-501: phase 2 study investigating the role of epigenetic therapy with entinostat (SNDX-275) in relapsed and refractory Hodgkin’s lymphoma (HL), interim results. (ASH Ann. Meet. Abstr.) Blood, 2010, 116(21), 3959.

  • 45

    Fehniger, T. A., Larson, S., Trinkaus, K., et al.: A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood, 2011, 118(19), 5119–5125.

  • 46

    Johnston, P. B., Inwards, D. J., Colgan, J. P., et al.: A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am. J. Hematol., 2010, 85(5), 320–324.

  • 47

    Johnston, P. B., Pinter-Brown, L., Rogerio, J., et al.: Open-label, single-arm, Phase II study of everolimus in patients with relapsed/refractory classical Hodgkin lymphoma. (ASH Ann. Meet. Abstr.) Blood, 2011, 118(21), 2717.

All Time Past Year Past 30 Days
Abstract Views 66 66 21
Full Text Views 10 2 0
PDF Downloads 10 3 0